OXFORD, England – Ochre Bio, a pioneer in chronic liver disease medicine development, today announced that Jack O’Meara has stepped down as Chief Executive Officer and member of the Board of Directors. Dr. Eliot Forster, who joined Ochre as Chairperson in 2023, will take on the role of Executive Chairperson in an interim capacity.
Eliot Forster, PhD, Executive Chairperson at Ochre Bio, said:
“Jack co-founded the company in 2019 and has taken it from a start-up to a leader in liver diseases. Under Jack’s leadership, Ochre closed several rounds of financing from top tier investors. Ochre also recently closed two high-value pharma partnerships with GSK & BI. Jack steps away with Ochre Bio poised for a successful future with a strong financial and science foundation. On behalf of myself and the board, we would like to express our sincere appreciation for Jack’s achievements as CEO of Ochre Bio.”
Jack O’Meara said:
“It has been a rare privilege to have helped build Ochre from an idea on a page to a biotech that is a leader in technology-enabled drug discovery, and a business with a strong set of values and culture. As the company heads into its next phase, the time has come for me to pass the baton as CEO. I feel a deep sense of pride in what we have collectively achieved and gratitude for the kindness shown to me by countless folks along the way. I have no doubt that this outstanding team will have a profound impact on the treatment of liver diseases.”
–
About Ochre Bio:
Ochre Bio is a biotechnology company developing novel RNA medicines for under-treated chronic liver diseases. Its proprietary discovery platform combines machine learning and big human datasets, with in-house RNA chemistry, and testing in live human donor livers. Ochre Bio is headquartered in Oxford, UK, and has research labs in New York and Taipei.
